FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Last trade$0.91
Day change+$0.0066 (+0.73%)
Day range$0.898 – $0.952
Volume61,557
Market cap$6M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.37M
Price / earnings
—
Price / book
1.37×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.18×
Profitability
Earnings per share
-$2.56
Return on assets
-228.77%
Return on equity
-391.26%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.64×
Quick ratio
2.64×
Cash ratio
1.59×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$14.8M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FBLG, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.38M
$2.12M
$1.79M
$2.25M
$2.45M
$2.75M
$2.36M
$2.14M
Research and development
$1.66M
$2.95M
$797K
$2.79M
$2.04M
$1.78M
$1.36M
$1.21M
Total operating expenses
$4.03M
$5.07M
$2.59M
$5.04M
$4.49M
$4.53M
$3.71M
$3.35M
Operating income
-$4.03M
-$5.07M
-$2.59M
-$5.04M
-$4.49M
-$4.53M
-$3.71M
-$3.35M
Interest expense
-$7K
-$4K
-$204K
$0
$0
$0
-$6K
-$5K
Income before taxes
-$4.12M
-$5M
-$3.24M
-$5.78M
-$4.66M
-$4.97M
-$3.1M
-$500K
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.12M
-$5M
-$3.24M
-$5.78M
-$4.66M
-$4.97M
-$3.1M
-$500K
Net income attributable to common shareholders
-$4.12M
-$5M
-$3.24M
-$5.78M
-$4.66M
-$4.97M
-$3.1M
-$500K
EBITDA
-$3.97M
-$5M
-$1.94M
-$4.97M
-$4.43M
-$4.48M
-$3.25M
-$3.31M
Basic earnings per share
-$0.66
-$1.33
-$1.08
-$2.60
-$2.41
-$2.71
-$1.82
-$0.20
Diluted earnings per share
-$0.66
-$1.33
-$1.08
-$2.60
-$2.41
-$2.71
-$1.82
-$0.20
Recent news
Company coverage with links to the original publishers.
FibroBiologics announced completion of cGMP manufacturing for CYWC628 drug product and site onboarding for a phase 1/2 clinical trial in diabetic foot ulcers, with first patient dosing expected in Q2 2026. The company reported positive preclinical results for burn and degenerative disc disease programs, raised $3M in capital, and regained full Nasdaq compliance. Q1 2026 showed R&D expenses of $3.0M and a net loss of $5.0M, with cash reserves of $1.5M at quarter-end.
Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.
FibroBiologics priced a public offering of 2.27 million shares and warrants at $1.32 per share, expecting to raise approximately $3 million in gross proceeds before fees. The company also announced successful manufacturing of CYWC628 drug product to support an upcoming diabetic foot ulcer clinical trial. Additionally, the company completed a reverse stock split to regain Nasdaq compliance with bid price requirements.
The global cell therapy market is projected to surpass $8.2 billion in 2026, with CAR T-cell therapy expanding at 18% annually. Several companies are advancing manufacturing milestones and clinical breakthroughs: Avaí Bio initiated Master Cell Bank production for α-Klotho anti-aging therapy; FibroBiologics secured a patent for fibroblast cell therapy for osteoporosis; Fate Therapeutics achieved same-day hospital discharge for off-the-shelf CAR T-cell patients; Mesoblast presented favorable survival data for Ryoncil® in graft-versus-host disease; and Longeveron published Phase 2b results showing stem cell therapy improved physical condition in age-related frailty patients.
FibroBiologics, a clinical-stage biotechnology company, closed a $4 million registered direct offering by issuing common stock and pre-funded warrants to an existing shareholder, with proceeds intended for general corporate purposes and debt satisfaction.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.